Commissioning of high-cost drugs in the NHS
Escalating drug use and associated expenditure has been a cause of concern for many governments over the years. In 1994 the Department of Health (DH) introduced guidance to secondary care on the managed entry of new drugs via its executive letter EL(94) 72. This required hospitals to take a more robust approach to the introduction of new technologies and take into account the primary care perspective of its service commissioners.
Dermatology in practice 2005; 13(4): 20–22
To continue reading this article, please sign in or register.